Genmab — Juli 2024

ProinvestorNEWS

Torsdagens aktier: Genmab skilte sig positivt ud i presset C25 https://proinvestor.com/investornyt/1190286/torsdagens-aktier-genmab-skilte-sig-positivt-ud-i-presset-c25

bikube

E L gav os nyheden kl. 13,45, men der gik 1-2 timer, før markedet var med.

JKY_VH

respekt:-)

Raun

@Pensionisten med 1% stigning i US. så får jeg kursen til 1930dkr

Solsen

Epkinly $17/27/63 mln i hhv Q4/Q1/Q2 jf https://proinvestor.com/investornyt/1190236/genmabs-kraefthab-viser-fortsat-solide-vaekstrater - det tegner godt

E_L

either I am dyslexic or thiose journalists are.. i thought it was 36mn, not 63?

E_L

and i don't think they realise that this is the abbvie part, so total sales are approx double

Solsen

Iam not sure how they account the revenue. Genmab take 50% in US and Japan all other goes til Abbvie is my belive. But absolutely not sure.

Solsen

De $63 mln kan være 6 mdr jf Abbvies regnskab så tallene kan være $17/23/36 for de sidste 3 kvartaler. Genmab omtaler at de indregner US og Japan (record) og modtager 22-26% royalty for rw. Men der er noget der ikke passer her

E_L

That is corect. it was easy up to now; it was 50/50 as sales were practically all US. But with more sales in Europe it will not end up being AbbVie sales *2 anymore at some point

Solsen

Genmab says in annual report 2023 that they recorded $61 mln revenue of Epkinley.

Solsen

https://investors.abbvie.com/static-files/81a1993c-c366-44dc-89d7-106c21327573 p43. Abbvie in 2023: collaboration revenue $28 mln and International $3 mln.

Solsen

Revenue outside US and Japan in 2023: $3 mln. Revenue US and Japan $61 mln. Total 2023 for Epkinly: $64 mln (perhaps)

Solsen

https://investors.abbvie.com/static-files/c9936258-3a4c-48f0-968b-6d533ead6dee p7. If we take 3 month “revenue” data 14+22=36 then I belive real Epkinly revenue could be 31+32=63 (US+RW=Total) and the souce could right. My estimate is 45% of US revenue as collaboration revenu and Japan 8 mln out of the 22 mln recorded by Abbvie. If its true Genmab should record $38-40 mln in Q2 as Epkinly revenue. But hope we somewhere will get the revenue figures more easy

E_L

you have to start dialing a Danish phone number now if
you want Trial Information on PRO1184 https://www.clinicaltrials.gov/study/NCT05579366?tab=history&a=16&b=17#version-content-panel

E_L

AbbVie (ABBV) Q2 2024 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/07/25/abbvie-abbv-q2-2024-earnings-call-transcript/

E_L

" we continue to be pleased with the prescription trends for Epkinly in DLBCL. Commercialization is now underway for Epkinly's second indication, follicular lymphoma, in the U.S.

with European approval expected later this year."

E_L

"
In the area of hematologic oncology, we received accelerated approval in the U.S. for Epkinly as a monotherapy treatment for patients with relapsed/refractory follicular lymphoma after two or more lines of prior therapy. Epkinly is now the only T-cell-engaging bispecific approved in the U.S.

to treat both follicular lymphoma and diffuse large B-cell lymphoma. We're extremely excited to bring this new subcutaneous treatment option to patients suffering from follicular lymphoma.

E_L

We also recently received positive CHMP opinion with an approval decision in Europe expected later this year"

E_L

@Solsen medwatch corrected following your analysis
https://medwatch.dk/Medicinal___Biotek/article17305159.ece